NASDAQ$ATYR
aTyr Pharma Inc · Q3 2024 earnings
Q3 2024 earnings ·
Briefing
ATYR Q3 2024 — $200K revenue
The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. aTyr Pharma Inc reported Q3 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $200K.
- Filed on Form 10-Q (accession 0000950170-24-123305).
Headline financials
Revenue & EPS history
aTyr Pharma Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2024
-2.0%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+10.0%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+7.4%
Q2 2020
Best reaction
-8.6%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -8.6% | +2.2% | -6.1% | |
| Q3 2025 | -5.4% | -3.3% | +1.2% | |
| Q1 2025 | -2.2% | +0.3% | +66.6% | |
| Q3 2024 | -4.6% | +7.4% | +3.4% | |
| Q2 2024 | -3.9% | +5.5% | +3.3% | |
| Q1 2024 | +0.6% | +6.9% | +8.8% | |
| Q3 2023 | -5.7% | -9.0% | -1.6% | |
| Q4 2022 | +1.0% | -3.6% | -1.0% | |
| Q4 2021 | +0.0% | +6.5% | +4.2% | |
| Q3 2021 | +1.2% | -1.7% | -7.0% | |
| Q2 2021 | +0.8% | -2.3% | +14.2% | |
| Q1 2021 | +1.7% | +11.6% | +31.2% | |
| Q3 2020 | +0.6% | -1.8% | +38.1% | |
| Q2 2020 | +7.4% | +20.6% | -1.4% | |
| Q1 2020 | -5.4% | -6.1% | -15.9% | |
| Q3 2019 | -6.2% | -3.9% | +7.2% | |
| Q2 2019 | -5.7% | +4.7% | +24.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro